Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 23891987)

1.

Nanoscale artificial antigen presenting cells for T cell immunotherapy.

Perica K, De León Medero A, Durai M, Chiu YL, Bieler JG, Sibener L, Niemöller M, Assenmacher M, Richter A, Edidin M, Oelke M, Schneck J.

Nanomedicine. 2014 Jan;10(1):119-29. doi: 10.1016/j.nano.2013.06.015. Epub 2013 Jul 24.

2.

In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Durai M, Krueger C, Ye Z, Cheng L, Mackensen A, Oelke M, Schneck JP.

Cancer Immunol Immunother. 2009 Feb;58(2):209-20. doi: 10.1007/s00262-008-0542-1. Epub 2008 Jun 18.

3.

Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.

Yu X, He J, Mongkhoune S, Peng Y, Xie Y, Su J, Zhou SF, Xie XX, Luo GR, Fang Y, Li X, Li X, Zhou N, Zhao YX, Lu XL.

Asian Pac J Trop Med. 2013 Jun;6(6):467-72. doi: 10.1016/S1995-7645(13)60076-0.

4.

In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP, Bronte V.

Cancer Res. 2009 Dec 15;69(24):9376-84. doi: 10.1158/0008-5472.CAN-09-0400. Epub .

5.

Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.

Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N.

Clin Cancer Res. 2007 Mar 15;13(6):1857-67.

6.

A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.

Han H, Peng JR, Chen PC, Gong L, Qiao SS, Wang WZ, Cui ZQ, Yu X, Wei YH, Leng XS.

Biochem Biophys Res Commun. 2011 Aug 5;411(3):530-5. doi: 10.1016/j.bbrc.2011.06.164. Epub 2011 Jul 2.

PMID:
21756876
7.

Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.

Lu X, Jiang X, Liu R, Zhao H, Liang Z.

Cancer Lett. 2008 Nov 18;271(1):129-39. doi: 10.1016/j.canlet.2008.05.049. Epub 2008 Jul 14.

PMID:
18621475
9.

Latex bead-based artificial antigen-presenting cells induce tumor-specific CTL responses in the native T-cell repertoires and inhibit tumor growth.

Shen C, Cheng K, Miao S, Wang W, He Y, Meng F, Zhang J.

Immunol Lett. 2013 Feb;150(1-2):1-11. doi: 10.1016/j.imlet.2013.01.003. Epub 2013 Jan 14.

PMID:
23328744
10.

Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity.

Perica K, Tu A, Richter A, Bieler JG, Edidin M, Schneck JP.

ACS Nano. 2014 Mar 25;8(3):2252-60. doi: 10.1021/nn405520d. Epub 2014 Feb 24.

11.

Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.

Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP.

Nat Med. 2003 May;9(5):619-24. Epub 2003 Apr 21.

PMID:
12704385
12.

Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.

Ye Q, Loisiou M, Levine BL, Suhoski MM, Riley JL, June CH, Coukos G, Powell DJ Jr.

J Transl Med. 2011 Aug 9;9:131. doi: 10.1186/1479-5876-9-131.

13.

Linking form to function: Biophysical aspects of artificial antigen presenting cell design.

Perica K, Kosmides AK, Schneck JP.

Biochim Biophys Acta. 2015 Apr;1853(4):781-790. doi: 10.1016/j.bbamcr.2014.09.001. Epub 2014 Sep 6. Review.

PMID:
25200637
14.

Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.

Obermann S, Petrykowska S, Manns MP, Korangy F, Greten TF.

Immunology. 2007 Sep;122(1):90-7. Epub 2007 Apr 30.

15.

HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL.

Chiu YL, Schneck JP, Oelke M.

J Vis Exp. 2011 Apr 11;(50). pii: 2801. doi: 10.3791/2801.

16.

4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH, Mackall CL.

J Immunol. 2007 Oct 1;179(7):4910-8.

17.

Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis.

Xu Z, Ramishetti S, Tseng YC, Guo S, Wang Y, Huang L.

J Control Release. 2013 Nov 28;172(1):259-65. doi: 10.1016/j.jconrel.2013.08.021. Epub 2013 Sep 1.

PMID:
24004885
18.
19.

Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells.

Sunshine JC, Perica K, Schneck JP, Green JJ.

Biomaterials. 2014 Jan;35(1):269-77. doi: 10.1016/j.biomaterials.2013.09.050. Epub 2013 Oct 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk